Vertex Pharmaceuticals/$VRTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
- Ticker
- $VRTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,400
- Headquarters
- Boston, United States
- Website
- www.vrtx.com
VRTX Metrics
BasicAdvanced
$131B
30.05
$17.18
0.30
-
Price and volume
Market cap
$131B
Beta
0.3
52-week high
$560.25
52-week low
$374.17
Average daily volume
1M
Financial strength
Current ratio
3.185
Quick ratio
2.536
Long term debt to equity
0.098
Total debt to equity
0.098
Interest coverage (TTM)
369.14%
Profitability
EBITDA (TTM)
5,099.9
Gross margin (TTM)
54.96%
Net profit margin (TTM)
35.00%
Operating margin (TTM)
39.00%
Effective tax rate (TTM)
16.48%
Revenue per employee (TTM)
$1,970,000
Management effectiveness
Return on assets (TTM)
11.93%
Return on equity (TTM)
23.54%
Valuation
Price to earnings (TTM)
30.051
Price to revenue (TTM)
10.43
Price to book
6.46
Price to tangible book (TTM)
6.98
Price to free cash flow (TTM)
34.583
Free cash flow yield (TTM)
2.89%
Free cash flow per share (TTM)
14.931
Growth
Revenue change (TTM)
10.23%
Earnings per share change (TTM)
22.12%
3-year revenue growth (CAGR)
9.81%
10-year revenue growth (CAGR)
23.24%
3-year earnings per share growth (CAGR)
9.92%
10-year earnings per share growth (CAGR)
31.24%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Analyst projections of the future price of Vertex Pharmaceuticals stock.
Bulls say / Bears say
Vertex delivered 12% second-quarter revenue growth and raised its 2026 revenue guidance to $13.1 billion-$13.2 billion. Continued uptake of ALYFTREK and strong demand for the wider cystic-fibrosis portfolio are supporting growth from an already profitable base. (Financial Times)
The newer products are gaining traction: second-quarter CASGEVY revenue reached $76 million and JOURNAVX revenue reached $50 million, with both showing strong sequential growth. Vertex expects at least $500 million of combined non-CF revenue in 2026, indicating that diversification is beginning to contribute materially. (The Motley Fool)
The completed Crinetics acquisition adds rare endocrinology as another commercial pillar, alongside an acromegaly product and a late-stage congenital adrenal hyperplasia candidate. This broadens Vertex’s specialty-medicine platform and should reduce its reliance on cystic fibrosis over time. (Transcript Daily)
Cystic fibrosis still dominates Vertex’s sales: CF product revenue was about $3.21 billion of $3.33 billion total in the second quarter, while TRIKAFTA/KAFTRIO revenue fell 2% year on year. Diversification is growing, but a setback in the core franchise would still have an outsized effect. (The Motley Fool)
JOURNAVX’s second-quarter revenue reached $50 million, but management warned that wholesaler inventory and formulary adoption can make reported sales volatile. Earlier sales also fell short of initial expectations, so rising prescriptions have yet to prove durable, high-value commercial uptake. (The Motley Fool, PharmaVoice)
The non-CF growth thesis still depends on major execution points: povetacicept awaits an FDA decision on 30 November, while inaxaplin and peripheral-neuropathy pain programmes remain in development. Delays or disappointing data would leave the CF franchise carrying the growth burden for longer. (Markets Daily, Transcript Daily)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
VRTX News
AllArticlesVideos
Funds containing VRTX
AllUSDGBPEUR
Fund name | Fund size | $VRTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 8.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 8.14% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.15% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.75% |
iShares Edge S&P 500 Minimum Volatility$SPMV | $1.9B | 0.97% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.